Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Capital Expenditures (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Capital Expenditures for 16 consecutive years, with $452000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 100.62% to $452000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $452000.0 through Dec 2025, down 75.18% year-over-year, with the annual reading at $452000.0 for FY2025, 75.18% down from the prior year.
  • Capital Expenditures hit $452000.0 in Q4 2025 for Ligand Pharmaceuticals, up from -$428000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $74.5 million in Q3 2024 to a low of -$73.2 million in Q4 2024.
  • Historically, Capital Expenditures has averaged $1.4 million across 5 years, with a median of $311000.0 in 2024.
  • Biggest YoY gain for Capital Expenditures was 60658.54% in 2024; the steepest drop was 17792.18% in 2024.
  • Year by year, Capital Expenditures stood at $8.2 million in 2021, then tumbled by 74.02% to $2.1 million in 2022, then plummeted by 119.19% to -$409000.0 in 2023, then plummeted by 17792.18% to -$73.2 million in 2024, then skyrocketed by 100.62% to $452000.0 in 2025.
  • Business Quant data shows Capital Expenditures for LGNDZ at $452000.0 in Q4 2025, -$428000.0 in Q3 2025, and $214000.0 in Q2 2025.